Compile Data Set for Download or QSAR
Report error Found 595 Enz. Inhib. hit(s) with all data for entry = 2457
TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244392(US9428502, 1 | US10226449, cpd 1 | US20250017938, ...)
Affinity DataEC50:  27nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244393(US9428502, 2 | US10226449, cpd 2 | US20250017938, ...)
Affinity DataEC50:  37nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244394(US9428502, 3 | US10226449, cpd 3 | US20250017938, ...)
Affinity DataEC50:  68nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244395(US9428502, 4 | US10226449, cpd 4 | US20250017938, ...)
Affinity DataEC50:  81nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244396(US9428502, 5 | US10226449, cpd 5 | US20250017938, ...)
Affinity DataEC50:  9nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244397(US9428502, 6 | US10226449, cpd 6 | US20250017938, ...)
Affinity DataEC50:  86nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244398(US9428502, 7 | US10226449, cpd 7 | US20250017938, ...)
Affinity DataEC50:  3nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244399(US9428502, 8 | US10226449, cpd 8 | US20250017938, ...)
Affinity DataEC50:  50nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244400(US9428502, 9 | US10226449, cpd 9)
Affinity DataEC50:  30nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244401(US9428502, 10 | US10226449, cpd 10 | US20250017938...)
Affinity DataEC50:  30nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244402(US9428502, 11 | US10226449, cpd 11 | US20250017938...)
Affinity DataEC50:  44nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244403(US9428502, 12 | US10226449, cpd 12 | US20250017938...)
Affinity DataEC50:  160nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244404(US9428502, 13 | US10226449, cpd 13 | US20250017938...)
Affinity DataEC50:  5nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244405(US9428502, 14 | US10226449, cpd 14 | US20250017938...)
Affinity DataEC50:  31nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244406(US9428502, 15 | US10226449, cpd 15 | US20250017938...)
Affinity DataEC50:  22nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244407(US9428502, 16 | US10226449, cpd 16 | US20250017938...)
Affinity DataEC50:  13nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244408(US9428502, 17 | US10226449, cpd 17 | US20250017938...)
Affinity DataEC50:  81nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244410(US9428502, 19 | US10226449, cpd 19 | US20250017938...)
Affinity DataEC50:  42nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244411(US9428502, 20 | US10226449, cpd 20 | US20250017938...)
Affinity DataEC50:  130nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244412(US9428502, 21 | US10226449, cpd 21 | US20250017938...)
Affinity DataEC50:  390nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244413(US9428502, 22 | US10226449, cpd 22 | US20250017938...)
Affinity DataEC50:  2.22E+3nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244414(US9428502, 23 | US10226449, cpd 23 | US20250017938...)
Affinity DataEC50:  93nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244415(US9428502, 24 | US10226449, cpd 24 | US20250017938...)
Affinity DataEC50:  97nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM367208(US10226449, cpd 25)
Affinity DataEC50:  19nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244418(US9428502, 27 | US10226449, cpd 27 | US20250017938...)
Affinity DataEC50:  5nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244419(US9428502, 28 | US10226449, cpd 28 | US20250017938...)
Affinity DataEC50:  11nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244420(US9428502, 29 | US10226449, cpd 29 | US20250017938...)
Affinity DataEC50:  9nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244421(US9428502, 30 | US10226449, cpd 30 | US20250017938...)
Affinity DataEC50:  13nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244422(US9428502, 31 | US10226449, cpd 31 | US20250017938...)
Affinity DataEC50:  3nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244423(US9428502, 32 | US10226449, cpd 32 | US20250017938...)
Affinity DataEC50:  3nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244426(US9428502, 35 | US10226449, cpd 35 | US20250017938...)
Affinity DataEC50:  2.78E+3nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244428(US9428502, 37 | US10226449, cpd 37 | US20250017938...)
Affinity DataEC50:  32nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244429(US9428502, 38 | US10226449, cpd 38 | US20250017938...)
Affinity DataEC50:  640nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244430(US9428502, 39 | US10226449, cpd 39 | US20250017938...)
Affinity DataEC50:  980nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244431(US9428502, 40 | US10226449, cpd 40 | US20250017938...)
Affinity DataEC50:  1.70E+3nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244433(US9428502, 42 | US10226449, cpd 42 | US20250017938...)
Affinity DataEC50:  115nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244434(US9428502, 43 | US10226449, cpd 43 | US20250017938...)
Affinity DataEC50:  4nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244435(US9428502, 44 | US10226449, cpd 44 | US20250017938...)
Affinity DataEC50:  3nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244436(US9428502, 45 | US10226449, cpd 45)
Affinity DataEC50:  2nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244437(US9428502, 46 | US10226449, cpd 46 | US20250017938...)
Affinity DataEC50:  4nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244438(US9428502, 47 | US10226449, cpd 47 | US20250017938...)
Affinity DataEC50:  3nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244439(US9428502, 48 | US10226449, cpd 48 | US20250017938...)
Affinity DataEC50:  4nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244440(US9428502, 49 | US10226449, cpd 49 | US20250017938...)
Affinity DataEC50:  3nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244441(US9428502, 50 | US10226449, cpd 50 | US20250017938...)
Affinity DataEC50:  250nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244442(US9428502, 51 | US10226449, cpd 51 | US20250017938...)
Affinity DataEC50:  51nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM367235(US10226449, cpd 52 | US20250017938, Compound 002-5...)
Affinity DataEC50:  280nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244444(US9428502, 53 | US10226449, cpd 53 | US20250017938...)
Affinity DataEC50:  100nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244445(US9428502, 54 | US10226449, cpd 54 | US20250017938...)
Affinity DataEC50:  33nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244446(US9428502, 55 | US10226449, cpd 55 | US20250017938...)
Affinity DataEC50:  320nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244447(US9428502, 56 | US10226449, cpd 56 | US20250017938...)
Affinity DataEC50:  32nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 595 total ) | Next | Last >>
Jump to: